President and Chief Executive Officer
Will Lewis joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Prior to Aegerion, Will spent more than 10 years working in the US and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. Will serves on the Boards of UniQure and Oberlin College. Will holds a Bachelor of Arts degree cum laude from Oberlin College, a Master of Business Administration from Case Western Reserve University and a Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.
Chief Financial Officer
Andy Drechsler joined Insmed as Chief Financial Officer in November 2012. He offers 15 years of financial and operational leadership experience in both public and private life sciences companies. Mr. Drechsler joins Insmed from VaxInnate Corporation, a privately held clinical-stage biotechnology company developing vaccines for infectious diseases, where he was Chief Financial Officer. During his five years with VaxInnate, he led multiple financing transactions totaling more than $55 million. Previously, he was Chief Financial Officer of publicly-traded Valera Pharmaceuticals where he helped raise $35 million through an initial public offering in 2006, completed a licensing and investment agreement with a partner for two products and worked with senior management to build a commercial team. Mr. Drechsler was part of the team that negotiated the sale of the company to Indevus Pharmaceuticals in 2007 in a transaction valued at $150 million. His public company and financial reporting duties have also included serving as controller for a variety of companies, including Abbott Laboratories’ Point of Care Division, which was publicly-traded as i-Stat Corporation prior to being acquired by Abbott, and Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme. Mr. Drechsler graduated Magna Cum Laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey.
General Counsel & Corporate Secretary
Christine Pellizzari joined Insmed in July 2013. She brings nearly 20 years of senior-level leadership experience in the global biotechnology and pharmaceutical industry. Most recently, Ms. Pellizzari served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., a publicly traded company developing therapies for rare diseases. Among her accomplishments and responsibilities at Aegerion, Ms. Pellizzari oversaw all the legal aspects of that company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee. Prior to joining Aegerion, Ms. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the global pharmaceutical industry. She was a member of the company's Executive Operations Management Committee and helped lead many critical initiatives during her 9 year tenure, including the sale of the company to Cegedim S.A. in May, 2007. Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. Before joining Wilentz, Ms. Pellizzari served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Ms. Pellizzari received her BA, cum laude, from the University of Massachusetts, Amherst and her JD from the University of Colorado, Boulder.
Walter Perkins, PhD
Chief Technology Officer
Walter Perkins joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Dr. Perkins joined Transave in 2002 and served as Chief Technology Officer. Dr. Perkins has over 20 years experience utilizing lipid-based drug delivery systems and has authored over 66 scientific publications and patent applications. Prior to joining Transave, Dr. Perkins spent 15 years with The Liposome Company (later a part of Elan Drug Delivery). At The Liposome Company, Dr. Perkins was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development and launch of the company's two commercial products Abelcet®
. As a part of Elan's Drug Delivery Division, he played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Dr. Perkins received his bachelor's and doctoral degrees in Biophysical Chemistry from the University of Virginia where he studied the physical and electrical properties of liposomal membranes.
Eugene Sullivan, M.D.
Chief Medical and Scientific Officer
Dr. Sullivan joined Insmed in March, 2015 as Chief Medical and Scientific Officer. Dr. Sullivan has more than 20 years of experience with a focus on pulmonary and orphan diseases. He is a medical doctor trained in internal medicine, pulmonary medicine and critical care medicine and practiced at the Cleveland Clinic from 1995 to 1999. From 1999 through 2006, Gene held several positions at the U.S. Food and Drug Administration, including Deputy Director of the Division of Pulmonary and Allergy Products. From 2007 through 2012, Dr. Sullivan was the Chief Medical Officer of United Therapeutics. In recent years, Dr. Sullivan was a Vice President, Global Regulatory Affairs at Astra Zeneca and consulted to companies, including Insmed, on clinical drug development and strategic regulatory matters. Dr. Sullivan graduated summa cum laude from the University of Maryland with a Bachelor of Science degree. He earned his medical degree from the University of Maryland, School of Medicine and conducted his internship and residency in Internal Medicine at the Medical College of Virginia. Dr. Sullivan completed his fellowship training in Pulmonary and Critical Care Medicine at the University of Colorado Health Sciences Center and received a Masters of Pulmonary Vascular Disease from the University of Bologna in Italy.
S. Nicole Schaeffer
Senior Vice President, Human Resources and Corporate Services
Ms. Schaeffer joined Insmed in October 2012. She brings more than 20 years of experience in Human Resources, organizational development, corporate operations and building life science organizations. Most recently Ms. Schaeffer served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities and IT functions. While at Amicus, Ms. Schaeffer was responsible for the organizational growth and development of this high performing company from its earliest stages to its current position as a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, she served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm, and in that capacity she managed human resources for three life sciences companies. She has also held HR leadership positions with Oak Industries and EMC Corporation. Ms. Schaeffer received her BA from the University of Rochester and her MBA from Boston University.